Roth Capital Initiates Coverage On Pelthos Therapeutics with Buy Rating, Announces Price Target of $57
Benzinga Newsdesk 11 months ago
NewsPrice TargetInitiationAnalyst Ratings
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Roth Capital analyst Jonathan Aschoff initiates coverage on Pelthos Therapeutics (AMEX:PTHS) with a Buy rating and announces Price Target of $57.
Roth Capital analyst Jonathan Aschoff initiates coverage on Pelthos Therapeutics (AMEX:PTHS) with a Buy rating and announces Price Target of $57.
